NanoLumens Displays Give New Life to Australian Malls

Malls all over Australia are getting a facelift. NanoLumens LED displays are being installed by Digital Place Solutions (DPS) in three major shopping centers in Melbourne, Darwin, and Sydney. Suspended from the ceiling and from the walls, the brilliant colors and relevant info, such as news and live TV, stop many shoppers in their tracks. 

The lightweight and minimal additional support or infrastructure makes NanoLumens ideal for large, open spaces like malls. Conventional walls often require extra support and offer a subpar image. The biggest displays average 22 ft by 12.5 ft and present exciting content for shoppers while streaming in advertisement revenue for shopping centers. 

These three most recent displays are a small sample of what’s happening in this market, making key areas like food courts and lobbies more engaging for customers and more profitable for shopping centers. DPS and NanoLumens continue to be excited by the success of their partnership and looks forward to future collaborations.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More